Intravenous cyclophosphamide in lupus nephritis: Twenty years reducing dose;Ciclofosfamida intravenosa en nefritis lúpica: Veinte años reduciendo dosis

Nefrologia

Volumn 27, Issue 1, 2007, Pages 12-22

  Frutos, M A ^a,b   Martin Gomez A ^a   De Ramon E ^a   Camps, M T ^a   Valera, A ^b   Garcia I ^a   Fernandez Nebro A ^a  

^a Hospital Universitario Carlos Haya

^b HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

Author keywords

Cyclophosphamide; Lupus nephritis; Systemic lupus erythematosus

Indexed keywords

CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; TIME;

ADULT; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFUSIONS, INTRAVENOUS; LUPUS NEPHRITIS; MALE; TIME FACTORS;

EID: 34447094491     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, Aydintug AO, Chwalinska-Sadowska H, De Ramón E, Fernández-Nebro A, Galeazzi M, Valen M, Mathieu A, Houssiau F, Caro N, Alba P, Ramos-Casals M, Ingelmo M; Hughes GR: European Working Party on Systemic Lupus Erythematosus. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 82: 299308, 2003.
2. Frutos MA, Calvar C, Valera A, Cabello M y López de Novales E. Insuficiencia renal aguda en la nefritis lúpica. Nefrología 12: 140-146, 1992.
3. Arce-Salinas CA, Villa AR, Martínez-Rueda JO, Muñoz L, Cardiel MH, Alcover-Valera J, Alarcón-Segovia D. Factors associated with chronic renal failure in 121 patients with diffuse proliferative lupus nephritis: a case-control study. Lupus 4: 197-203, 1995.
4. Fiehn C, Hajjar Y, Mueller K, Waldherr R, Ho AD, Andrassy K. Improved clinical outcome of lupus nephritis during the past decade: importance of early diagnosis and treatment. Ann Rheum Dis 62: 435-439, 2003.
5. Cameron JS. Lupus nephritis. J Am Soc Nephrol 10: 413-424, 1999.
6. Lewis EJ, Schwartz MM. Pathology of lupus nephritis. Lupus 14: 31-38, 2005.
7. Ginzler EM, Moldovan I. Systemic lupus erythematosus trials: successes and issues. Curr Opin Rheumatol 16: 499-504, 2004.
8. Balow JE. Clinical presentation and monitoring of lupus nephritis. Lupus 14: 25-30, 2005.
9. Gil CM, Rivera F, Crespo A, Egea JJ, Gil MT, Olivares J. Evolución de la nefritis lúpica grave tratada con ciclofosfamida parenteral y esteroides orales. Nefrología 19: 514-521, 1999.
10. rd, Klippel JH, Balow JE, le Riche G, Steimber AD, Plotz PH, Decker JL. Therapy of lupus nephritis. Controlled trial of prednisone and citotoxic drugs. N Engl J Med 314: 614-619, 1986.
11. Houssiau FA, Vasconcelos C, D'Cruz D, Sebastián GD, De Ramón E, Danielli MG, Abramovicz D, Blockmans D, Mathieu A, Direskenelli H, Galleazi M, Gul A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font'-Depresseux G, Cosyns JP, Cervera R. Immunosuppresive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial. A randomized trial of low-dose versus high dose intravenous cyclophosphamide. Artritis Rheum 46: 2121-2131, 2002.
12. Frutos MA, Rivilla A, García I, Burgos D, Valera A, Martín-Reyes G, Cabello M, López de Novales E. Tratamiento con ciclofosfamida intravenosa del lupus eritematoso sistémico severo. Nefrología 10: 88-93, 1990.
13. Mok CC, Ho CT, Siu YP, Chan KW, Kwan TH, Lau CS, Wong RW, Au TC. Treatment of diffuse proliferative lupus glomerulonephritis: a comparison of two cyclophosphamide-containing regimens. Am J Kidney Dis 38: 256-264, 2001.
14. Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL, Lau CS, Wong AK, Tong MK, Chan KW, Lai KN. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 343: 1156-1162, 2000.
15. Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, O'Nan P, Roth D. Sequential therapies for proliferative lupus nephritis. N Engl J Med 350: 971-980, 2004.
16. Ginzler E, Dooley MA, Aranow C, Kim MY, Buyon J, Merill JT, Petri M, Gilkeson GS, Wallace DJ, Weisman MH, Appel GB. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 353: 2219-2228, 2005.
17. Hochberg MC. Updataing the American College of Rheumatollogy revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40: 1725, 1997.
18. Churg J, Sobin LH. Lupus nephritis. En: Churg J, Sobin LH eds.: Renal disease, classification and atlas of glomerular diseases. New York, NY, Igaku-Shoin, 1982, p. 127-149.
19. Donadio JV Jr, Holley KE, Ferguson RH, Ilstrup DM: Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide. N Engl J Med 299: 1151-1155, 1978.
20. Steinberg AD, Steinberg SC. Long-term preservation of renal fucntion in patients with lupus nephritis receaiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum 34: 945-950, 1991.
21. Austin HA, Boumpas DT. Treatment of lupus nephritis. Semin Nephrol 16: 527-535, 1996.
22. Frutos MA. Nefritis lúpica: tratamientos para hoy y mañana. Nefrología 21: 4-5, 2001.
23. Boumpas DT, Austin HA, Vaughn EM, Klippel JH, Steinberg AD, Yarboro CH, Balow JE. Controlled trial of pulse methylpredisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 340: 741-745, 1992.
24. Rivera F. López-Gómez JM. Pérez-García R. Spanish Registry of Glomerulonephritis. Clinicopathologic correlations of renal pathology in Spain. Kidney Int 66: 898-904, 2004.
25. Weening JJ. D'Agati VD. Schwartz MM. Seshan SV. Alpers CE. Appel GB. Balow JE. Bruijn JA. Cook T. Ferrario F. Fogo AB. Ginzler EM. Hebert L. Hill G. Hill P. Jennette JC. Kong NC. Lesavre P. Lockshin M. Looi LM. Makino H. Moura LA. Nagata M. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 65: 521-30, 2004.
26. Mittal B, Rennke H, Singh AK. The role of kidney biopsy in the management of lupus nephritis. Curr Opin Nephrol Hypert 14: 1-8, 2005.
27. Frutos MA, Cabello M, Valera A, Aranda P, González-Molina M, Martínez-González JM, Ramos B, Ruiz A, Martínez- González JL y López de Novales E.: Nefritis lúpica: Estudio clínico y evolución de 18 pacientes con insuficiencia renal. Nefrología 4: 205-210, 1984.
28. Esdaile JM, Joseph L, MacKenzie T, Kashgarian M, Hayslett JP. The pathogenesis and prognosis of lupus nephritis: information from repeat renal biopsy. Sem Arthr Rheum 23: 135-148, 1993.
29. Ponticelli C, Moroni G. Renal biopsy in lupus nephritis: what for, when and how often. Nephrol Dial Transpl 13: 2452-2454, 1998.
30. Austin HA III, Muenz LR, Joyce KM. Prognostic factors in lupus nephritis. Contributions of renal histological data. Am J Med 75: 382-391, 1983.
31. Schwartz MM, Lan SP, Bernstein J, Hill GS, Holley K, Lewis J. Irreproducibility of the activity and chronicity indices limits their utility in the management of lupus nephritis. Lupus Nephritis Collaborative Study Group. Am J Kidney Dis 21: 374-377, 1993.
32. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomized controlled trial. Lancet 361: 117-124, 2003.
33. Luño J. Efecto del tratamiento combinado con IECAs y ARAs sobre la proteinuria y función renal en pacientes con glomerulonefritis crónica. Nefrología 22 (Supl. 2): 41-43, 2002.
34. Dooley, MA, Hogan S, Jennette C, Falk R. Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Kidney Int 51: 1188-1995, 1997.
35. Barr RG, Seliger S, Appel G, Zuniga R, D'agati V, Salmon J, Radhakrishnan J. Prognosis in proliferative lupus nephritis: the role of socio-economic status and race/ethnicity. Nephrol Dial. Transplant 18: 2039-2046, 2003.
36. Balow JE, Austin HA. III. Maintenance Therapy for Lupus Nephritis - Something Old, Something New. N Engl J Med 350: 1044-1046, 2004.
37. Mok CC, Ying KY, Ng WL, Lee KW, To CH, Lau CS, Sing Wong RW: Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide. Am J Med 119: 355.e26-355.e33, 2006.
38. Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, Crow MK, Schwartz JE, Paget SA, Devereux RB, Salmon JE. Prevalence and Correlates of Accelerated Atherosclerosis in Systemic Lupus Erythematosus. N Engl J Med 349: 2399-2406, 2003.
39. Park JC, Park YB, Jung SY, Chung IH, Choi KH, Lee SK. Risk of Ovarian Failure and Pregnancy Outcome in Patients With Lupus Nephritis Treated With Intravenous Cyclophosphamide Pulse Therapy. Obst Gynecol Survey 60: 148-150, 2005.
40. Kang I, Park SH. Infectious complications in SLE after immunosuppressive therapies. Curr Opin Rheumatol 15: 528-534, 2003.
41. Álvarez L, Gil CM, Jiménez del Cerro LA, Olivares J, Rivera F. Micofenolato mofetil en la nefritis lúpica. Nefrología 22: 24-32, 2002.
42. Moroni G, Greloni, GC, Ponticelli C. Late recurrence of lupus nephritis after long-term clinical remission. Nephrol Dial Transplant 16: 849-852, 2001.
43. Carlavilla A, Gutiérrez E, Ortuño T, Morales E, González E, Praga M. Relapse of lupus nephritis more than 10 years after complete remission. Nephrol Dial Transplant 20: 1994-1998, 2005.
44. Mok CC, Ying KY, Tang S y cols: Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. Arthr Rheum 50: 2559-2568, 2004.
45. Sidiropoulos PI, Kritikos HD, Boumpas DT. Lupus nephritis flares. Lupus 14: 49-52, 2005.
46. Houssiau FA, Vasconcelos C, D'Cruz D. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from the long term follow up of the Euro-Lupus Nephritis Trial. Arthritis Rheum 50: 3934-3940, 2004.
47. Frutos MA, González Molina M, Aranda P, Cabello M, Martín-Reyes G, Valera A, Ramos B, Ruiz A, López de Novales E. Ciclosporina en el tratamiento del lupus eritematoso sistémico grave. Nefrología 7: 396-400, 1987.
48. Mok, CC. Cyclophosphamide for Severe Lupus Nephritis: Where Are We Now? Arthritis Rheum 50: 3748-3750, 2004.
49. McCune WJ. Mycophenolate mofetil for lupus nephritis. N Engl J Med 353: 2282-2284, 2005.